Prognosis of patients with coronary artery disease and diabetes — what to look for DOI Creative Commons
А. А. Некрасов, Е. С. Тимощенко,

Т. А. Некрасова

et al.

Russian Journal of Cardiology, Journal Year: 2024, Volume and Issue: 29(9), P. 6030 - 6030

Published: Aug. 28, 2024

Patients with coronary artery disease (CAD) and diabetes are identified as a high cardiovascular risk group both in Russia abroad. Having similar paths of development progression atherosclerosis atherothrombosis, these diseases potentiate each other's thrombogenesis mechanisms. As result, ischemic events occur, making significant contribution to the mortality rates this patients. Influencing thrombus formation is one key links on way improving prognosis patients CAD diabetes. Modern antithrombotic therapy, including not only antiplatelet agent aspirin, but also anticoagulant rivaroxaban at dose 2,5 mg, allows for maximum impact thereby reducing risks all-cause death. The aim review was analyze potential death by prescribing main drug groups that part therapy

Language: Английский

Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S) DOI
Timo Strandberg, Petri T. Kovanen, Donald M. Lloyd‐Jones

et al.

The Lancet, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 1, 2024

Language: Английский

Citations

6
Inflammatory cytokines and oral lichen planus: a Mendelian randomization study DOI Creative Commons
Xin Chen, Simin Zhang, Xiao Wu

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Feb. 7, 2024

Background Inflammatory cytokines have long been considered closely related to the development of oral lichen planus (OLP), and we further explored causal relationship between two by Mendelian randomization (MR) method. Methods We performed bidirectional MR analyses large genome-wide association studies (GWAS). The data included a large-scale OLP dataset, as well datasets 41 inflammatory cytokines. All were obtained from University Bristol database, which includes cytokines, GWAS Catalog 91 Finngen 6411 cases 405770 healthy controls. used inverse variance weighted (IVW) method, MR-Egger median simple mode method analyze OLP, also combined with sensitivity analysis verify robustness results. meta-analysis positive or potentially results for same genes confirm reliability final Results primarily IVW corrected using Benjamin Hochberg (BH) When p<0.00038 (0.05/132), are significantly causal; when 0.00038<p<0.05, causal. found total 7 significant potential associations (University database: 2, 5). In reverse analysis, that 30 associated 5, 25). After meta-analysis, finally determined there was 3 in forward most FGF21 (p=0.02954, odds ratio (OR): 1.113, 95% confidence interval (95%CI): 1.011-1.226). 14 causally PLAU (p=0.00002, OR: 0.951, 95%CI: 0.930-0.973). Conclusion There is some may play an important role pathogenesis require attention.

Language: Английский

Citations

5
The Effect of PCSK9 Monoclonal Antibodies on Platelet Reactivity and Cardiovascular Events in Patients Receiving Primary Percutaneous Coronary Intervention: A Propensity Score-Matched Analysis DOI
Yao Yao,

Qining Qiu,

Zi Wang

et al.

American Journal of Cardiovascular Drugs, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 15, 2025

Language: Английский

Citations

0
Lipidstoffwechselstörungen DOI

Bastian Schirmer,

Jochen Schuler

Springer eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 305 - 323

Published: Jan. 1, 2025

Citations

0
Relevance of Lipoprotein Composition in Endothelial Dysfunction and the Development of Hypertension DOI Open Access
Lisette Monsibaez Ramírez-Melo, Diego Estrada-Luna, María Esther Rubio-Ruiz

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(3), P. 1125 - 1125

Published: Jan. 28, 2025

Endothelial dysfunction and chronic inflammation are determining factors in the development progression of degenerative diseases, such as hypertension atherosclerosis. Among shared pathophysiological characteristics these two diseases is a metabolic disorder lipids lipoproteins. Therefore, contents quality proteins lipoproteins become targets therapeutic objective. One stages lipoprotein formation occurs through incorporation dietary by enterocytes into chylomicrons. Consequently, composition, structure, especially properties could be modified intake bioactive compounds. The objective this review to describe roles different lipid protein components their receptors endothelial hypertension. In addition, we use some non-pharmacological treatments that improve function and/or prevent damage. reviewed information contributes understanding vehicles regulatory involved modulation inflammatory hemostatic processes, attenuation oxidative stress, neutralization toxins, rather than only cholesterol phospholipid transporters. For review, bibliographic search was carried out online metabases.

Language: Английский

Citations

0
Flexible Approaches Based on Multistate Models and Microsimulation to Perform Real-World Cost-Effectiveness Analyses: An Application to Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors DOI Creative Commons
Caterina Gregorio, Federico Rea, Francesca Ieva

et al.

Value in Health, Journal Year: 2024, Volume and Issue: 27(7), P. 897 - 906

Published: March 26, 2024

Language: Английский

Citations

2
Efficacy and Safety of Lipid-Lowering Therapies in Combination With or Without Statin to Reduce the Cardiovascular Risk: A Systematic Review of Randomised Controlled Trials DOI Creative Commons
Gabriella Iannuzzo,

G Kamboj,

Pranab Barman

et al.

Atherosclerosis Plus, Journal Year: 2024, Volume and Issue: 58, P. 24 - 37

Published: Oct. 17, 2024

Language: Английский

Citations

2
Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis DOI Creative Commons
Suyi Zhang, Lei Sun, Xinyu Xu

et al.

BMC Cardiovascular Disorders, Journal Year: 2024, Volume and Issue: 24(1)

Published: Nov. 9, 2024

Hyperlipidemia plays a crucial role in increasing the risk of cardiovascular diseases such as atherosclerosis. Recent studies have established that inclisiran positively influences lipid regulation. Nevertheless, its effectiveness comparison to conventional treatments is still questionable. Hence, methodical assessment and safety required. This research evaluates efficacy inclisiran, PCSK9 inhibitors, combination statins with ezetimibe treatment hyperlipidemia via network meta-analysis randomized controlled trials (RCTs). We performed an extensive search English-language publications PubMed, Medline, Embase, Cochrane Library databases until April 2024. conducted web-based reported accordance guidelines. selected percentage change low-density lipoprotein cholesterol (LDL-C), total (TC), triglycerides (TG), high-density (HDL-C) evaluation metrics incidence adverse events for analysis comparison. incorporated 33 involving 23,375 patients, evaluating three interventions regarding their effects on LDL-C, TC, TG, HDL-C, events. All improved over placebo. Inclisiran significantly reduced LDL-C compared (mean − 15.21, 95% CI [-25.19, -5.23]) but showed no significant difference from statin + ezetimibe. Surface under cumulative ranking curve (SUCRA) rankings placed highest reduction (26.2%). The was most efficacious triglyceride 17.2, [10.22, 24.19]; mean 15.61, [16.87, 24.35]). profiles were comparable across treatments. superior low frequency administration, appears promising treatment, particularly patients adherence issues or side other medications. CRD42024550852

Language: Английский

Citations

2
PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes DOI Creative Commons
Daniela Grejtáková, Iveta Boronova, Jarmila Bernasovská

et al.

Cardiovascular Drugs and Therapy, Journal Year: 2024, Volume and Issue: unknown

Published: June 22, 2024

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a crucial role in the modulation of lipid metabolism as critical negative regulator hepatic low-density lipoprotein receptor (LDLR) levels and circulating (LDL) clearance. Numerous gain-of-function (GOF) mutations PCSK9 have been identified causing familial hypercholesterolemia (FH) by reducing LDLR levels, loss-of-function (LOF) associated with phenotype protective against atherosclerosis. represents an example successful translational research resulting identification major drug target for lipid-lowering therapy. To explore genetic constitution its biologic role, this review, we summarize current evidence clinically significant variants involved well emphasize importance inhibition improvement cardiovascular outcomes conducting meta-analysis available data on incidence disease events.

Language: Английский

Citations

1
Advances in the pharmacological management of hyperlipidemia through the use of combination therapies DOI
Anthony S. Wierzbicki

Expert Opinion on Pharmacotherapy, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 9

Published: Dec. 22, 2024

Lipid-lowering therapies are well established for the treatment of cardiovascular disease (CVD). Historically monotherapy studies have been performed, but introduction statins has led to these drugs being recognized as baseline and investigation combination therapy both older newer medications with them.

Language: Английский

Citations

1